You just read:

Data from Phase 3 studies of Gilead's sofosbuvir for hepatitis C to be presented at 48th Annual EASL Meeting; Findings published online today in The New England Journal of Medicine

News provided by

Gilead Sciences, Inc.

Apr 23, 2013, 12:17 ET